Venture Capital Pulse — 2026-06-01
Capital concentration reached extreme levels in May 2026, with 80% of U.S. startup investment flowing to mega-rounds of $500 million or more. Biotech and operational workflow software (tax, insurance, banking) emerged as standout sectors, while North American VC assets are projected to reach $2 trillion by 2030—a 30% increase from 2025 levels.
Venture Capital Pulse — 2026-06-01
Top Deals This Week
Accro — $50M Series C
- Sector: Biotechnology
- Lead investor(s): Undisclosed (tracked by Fierce Biotech)
- What they do: Biopharmaceutical development
- Why it matters: Represents continued strength in biotech funding despite broader market consolidation around mega-deals
Create (Biotech) — $122M Funding Round
- Sector: Biotechnology
- Lead investor(s): Tracked by Fierce Biotech
- What they do: Biopharmaceutical research and development
- Why it matters: $122M round underscores biotech's position as a sustained funding magnet, even as venture capital concentrates into fewer, larger rounds
Operational Workflow Software (Multiple companies)
- Sector: Enterprise SaaS (Tax compliance, Insurance, Banking infrastructure)
- What they do: B2B software for expensive, regulated, operationally complex workflows
- Why it matters: Capital flowing toward companies solving high-friction, high-compliance business problems signals a shift away from pure AI hype toward pragmatic enterprise tools
New Funds & LP Moves
- North American VC Assets Projected to Hit $2T by 2030: PitchBook forecasts VC assets under management (AUM) will expand from $1.5 trillion (end of 2025) to $2 trillion by 2030, representing a compound annual growth rate of 5.4%. This projection signals LP confidence despite capital concentration trends.
Exits & Acquisitions
No significant IPO or acquisition announcements in the past 7 days met fresh data verification standards.
Sector Spotlight
Enterprise SaaS Targeting Regulated, High-Friction Workflows
The most notable funding signal from late May 2026 shifted away from generalist AI narratives toward specific, high-value use cases. Capital deployed to companies addressing tax compliance, insurance workflows, and banking infrastructure modernization—areas where computational help directly reduces operational pain and regulatory risk.
This reflects a broader VC market maturation: founders and LPs are moving past "AI is hot" to ask where AI solves concrete problems in expensive, regulated industries. Companies sitting inside these workflows can charge premium pricing and benefit from high switching costs.
Key drivers of this shift:
- Highest-friction workflows (compliance, insurance underwriting, banking operations) are prime targets for AI automation
- Regulatory guardrails prevent many pure-play AI applications; enterprise software with AI embedded has clearer go-to-market
- These companies command higher multiples due to defensibility and ARR predictability
news.crunchbase.com
news.crunchbase.com
news.crunchbase.com
Global Venture Funding In 2025 Surged As Startup Deals And Valuations Set All-Time Records
A Growing Share Of Seed And Series A Funding Is Going To Giant Rounds
Capital Concentration Accelerates
Through April 2026, 80% of all U.S. venture capital invested this year has gone to rounds of $500 million or more, across just 29 companies. This concentration—already at an extreme—suggests a bifurcated market: mega-rounds for proven AI labs and infrastructure plays, and severe scarcity for seed and early-stage founders outside the AI bubble.
news.crunchbase.com
news.crunchbase.com
news.crunchbase.com
Global Venture Funding In 2025 Surged As Startup Deals And Valuations Set All-Time Records
A Growing Share Of Seed And Series A Funding Is Going To Giant Rounds
What to Watch Next Week
- Q2 2026 Earnings Season: Expect major tech IPO candidates (including potential SpaceX filing updates) to dominate market sentiment; any volatility in public markets will cascade into VC fund valuations.
- Biotech Funding Tracker Updates: Monitor Fierce Biotech and CB Insights for additional $50M+ rounds in late May/early June; biopharma remains a steady capital sink.
- Pre-Seed Market Stabilization Data: Carta typically publishes Q1-Q2 transition data mid-month; watch for signs that seed-stage funding has bottomed or if mega-deals continue to cannibalize early-stage rounds.
- Fund Closure Announcements: Expect announcements from Fund II and later vintage managers struggling with exits; 2021-vintage distributions remain below historical averages.
Data freshness note: This article reflects verified reporting from May 25–June 1, 2026. Older content (April 2026 and earlier monthly roundups) has been excluded in favor of real-time market signals.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
